ABSTRACT
INTRODUCTION: Most of the pregnant women do not achieve the recommended dietary intake of vitamins A and E. These vitamins may counteract oxidative stress involved in some adverse perinatal outcomes. We aimed to assess the associations between maternal vitamin A and E at mid-pregnancy with both maternal and fetal outcomes and to identify possible early biomarkers during pregnancy to predict and prevent oxidative stress in the offspring. METHODS: Data on dietary and serum levels of vitamins A and E were collected from 544 pregnant women from the Nutrition in Early Life and Asthma (NELA) study, a prospective mother-child cohort set up in Spain. RESULTS: There were large discrepancies between low dietary vitamin E intake (78% of the mothers) and low serum vitamin E levels (3%) at 24 weeks of gestation. Maternal serum vitamins A and E at mid-pregnancy were associated with higher antioxidant status not only in the mother at this time point (lower hydroperoxides and higher total antioxidant activity [TAA]) but also with the newborn at birth (higher TAA). Gestational diabetes mellitus (GDM) was negatively associated with maternal serum vitamin A (OR: 0.95 CI: 0.91-0.99, p = 0.009) at mid-pregnancy. Nevertheless, we could not detect any association between GDM and oxidative stress parameters. CONCLUSIONS: In conclusion, maternal vitamin A and E serum levels may be used as an early potential biomarker of antioxidant status of the neonate at birth. Control of these vitamins during pregnancy could help avoid morbid conditions in the newborn caused by oxidative stress in GDM pregnancies.
Subject(s)
Antioxidants , Diabetes, Gestational , Infant, Newborn , Female , Pregnancy , Humans , Vitamin A , Prospective Studies , Fetal Blood , Vitamins , Vitamin EABSTRACT
Background: Although adherence to the Mediterranean and antioxidant-rich diets during pregnancy is suggested to improve maternal-fetal health by reducing oxidative stress, yet there is no study available. Objective: We examined whether maternal dietary patterns in pregnancy impact the biomarkers of oxidative stress in mothers and their offspring. Methods: Study population included 642 mothers and 335 newborns of the "Nutrition in Early Life and Asthma" (NELA) birth cohort. Maternal diet during pregnancy was assessed by a validated food frequency questionnaire and a priori-defined dietary indices (relative Mediterranean Diet [rMED], alternative Mediterranean Diet [aMED], Dietary Approach to Stop Hypertension [DASH], Alternate Healthy Index [AHEI], and AHEI-2010) were calculated. Biomarkers measured were: hydroperoxides, carbonyl groups, and 8-hydroxydeoxyguanosine (8OHdG) determined in maternal blood and newborn cord blood, and urinary maternal and offspring 15-F2t-isoprostane. Multivariate linear regression models were performed. Results: Maternal rMED score was inversely associated with the maternal levels of 8OHdG at mid-pregnancy (beta per 1-point increase = -1.61; 95% CI -2.82, -0.39) and the newborn levels of hydroperoxides (beta per 1-point increase = -4.54; 95% CI -9.32, 0.25). High vs. low maternal rMED score was marginally associated with the decreased levels of 8OHdG in newborns (beta = -9.17; 95% CI -19.9, 1.63; p for trend 0.079). Maternal DASH score tended to be inversely associated with maternal urinary 15-F2t-isoprostane (beta per 1-point increase = -0.69; 95% CI, -1.44, 0.06). High vs. low maternal AHEI score was associated with reduced offspring urinary levels of 15-F2t-isoprostane (beta = -20.2; 95% CI -38.0, -2.46; p for trend 0.026). Conclusion: These results suggest that maternal adherence to healthy dietary patterns during pregnancy may reduce DNA damage and lipid oxidation in mothers and offspring.
ABSTRACT
Maternal supplementation of docosahexaenoic acid (DHA) during pregnancy has been recommended due to its role in infant development, but its effect on materno-fetal DHA status is not well established. We evaluated the associations between DHA supplementation in pregnant women with obesity or gestational diabetes mellitus (GDM) and maternal and neonatal DHA status. Serum fatty acids (FA) were analyzed in 641 pregnant women (24 weeks of gestation) and in 345 venous and 166 arterial cord blood samples of participants of the NELA cohort. Obese women (n = 47) presented lower DHA in serum than those lean (n = 397) or overweight (n = 116) before pregnancy. Linoleic acid in arterial cord was elevated in obese women, which indicates lower fetal retention. Maternal DHA supplementation (200 mg/d) during pregnancy was associated with enhanced maternal and fetal DHA levels regardless of pre-pregnancy body mass index (BMI), although higher arterial DHA in overweight women indicated an attenuated response. Maternal DHA supplementation was not associated with cord venous DHA in neonates of mothers with GDM. The cord arteriovenous difference was similar for DHA between GDM and controls. In conclusion, maternal DHA supplementation during pregnancy enhanced fetal DHA status regardless of the pre-pregnancy BMI while GDM may reduce the effect of DHA supplementation in newborns.
Subject(s)
Diabetes, Gestational/blood , Dietary Supplements , Docosahexaenoic Acids/analysis , Fatty Acids/blood , Obesity/blood , Pregnancy Complications/blood , Adult , Body Mass Index , Female , Fetal Blood/chemistry , Humans , Infant, Newborn , Male , Maternal Nutritional Physiological Phenomena , Pregnancy , Prospective StudiesABSTRACT
BACKGROUND: Acute intermittent porphyria (AIP) is a genetic disease characterized by acute neurovisceral attacks. Long-term clinical conditions, chronic symptoms and impaired health related quality of life (HRQoL) have been reported during non-attack periods but mainly in patients with recurrent attacks. Our aim was to investigate these aspects in sporadic AIP (SA-AIP) and latent AIP (L-AIP) patients. Fifty-five participants, 27 SA-AIP (< 4 attacks/year) and 28 L-AIP patients with a prevalent founder mutation from Spain were included. Medical records were reviewed, and individual interviews, physical examinations, biochemical analyses, and abdominal ultrasound scans were conducted. HRQoL was assessed through an EQ-5D-5L questionnaire. A comparative study was made between SA-AIP and L-AIP patients. RESULTS: The earliest long-term clinical condition associated with SA-AIP was chronic kidney disease. Chronic symptoms were reported in 85.2 % of SA-AIP and 46.4 % of L-AIP patients. Unspecific abdominal pain, fatigue, muscle pain and insomnia were significantly more frequent in SA-AIP than in L-AIP patients. The EQ-5D-5L index was lower in SA-AIP (0.809 vs. 0.926, p = 0.0497), and the impact of "pain", "anxiety-depression" and "mobility" was more intense in the EQ-5D-5L domains in SA-AIP than in L-AIP subjects and the general Spanish population. CONCLUSIONS: AIP remains a chronically symptomatic disease that adversely affects health and quality of life, even in patients with low rate of acute attacks. We suggest a regular monitoring of patients with symptomatic AIP regardless of their attack rate or the time since their last attack, with proper pain management and careful attention to kidney function.
Subject(s)
Porphyria, Acute Intermittent , Renal Insufficiency, Chronic , Humans , Quality of Life , Spain , Surveys and QuestionnairesABSTRACT
INTRODUCCIÓN: La discriminación entre enfermedades inflamatorias intestinales (EII) y trastornos funcionales gastrointestinales es compleja debido a que pueden presentar cuadros clínicos similares. La calprotectina fecal (CPF) es un marcador inflamatorio útil para este fin y permite seleccionar a los pacientes que más se pueden beneficiar de someterse a una colonoscopia. El objetivo fundamental de este estudio fue valorar la utilidad de la CPF para diferenciar entre enfermedades orgánicas y funcionales. MATERIAL Y MÉTODOS: Se determinó la concentración de CPF de 264 pacientes que presentaban signos o síntomas gastrointestinales indicativos de enfermedad orgánica, y se calculó su precisión diagnóstica mediante el área bajo la curva a partir del diagnóstico final. RESULTADOS: Los pacientes con enfermedad orgánica presentaron valores de CPF mayores (mediana 254 μg/g; intervalo de confianza [IC] 95%, rango intercuartil 105-588,5) que el grupo con enfermedad funcional (95 μg/g; IC 95%, 47,25-243,92; p < 0,0001), así como el grupo con EII (270,85 μg/g; IC 95%, 96,85-674,00) obtuvo valores más elevados que el grupo con síndrome del intestino irritable (79,70; IC 95%, 36,50-117,25; p < 0,0001). Para un valor de corte de 150 μg/g se obtuvo un valor del área bajo la curva de 0,718 para discriminar entre enfermedad orgánica y funcional, y de 0,872 para discriminar entre síndrome del intestino irritable y EII. CONCLUSIÓN: En este estudio se corrobora el alto valor de la CPF en la evaluación de pacientes con sospecha de EII. La mejor eficacia diagnóstica se consigue con un cut-off de 150μg/g para la discriminación entre EII y síndrome del intestino irritable
INTRODUCTION: Diagnostic discrimination between inflammatory bowel disease (IBD) and functional gastrointestinal disorders is complex, as they cause similar signs and symptoms. Faecal calprotectin (FC) is a useful marker in this context, and can be used to select patients who will most benefit from colonoscopy. The aim of this study was to evaluate the utility of FC in discriminating between organic disease and functional disorders. MATERIAL AND METHODS: The study included 264 patients presenting with gastrointestinal complaints consistent with an organic pathology. FC levels were determined and diagnostic accuracy was assessed using the area under the curve obtained from the final diagnosis. RESULTS: Calprotectin levels in organic bowel disease patients were significantly higher (median 254 μ g/g; 95% confidence interval [CI], interquartile range 105-588.5) than in functional disease patients (95 μ g/g; 95% CI, 47.25-243.92) (P < .0001). Similarly, in patients with IBD, the values obtained were higher (270.85 μg/g; 95% CI, 96.85-674.00) than in those with irritable bowel syndrome (79.70μ g/g; 95% CI, 36.50-117.25) (P<.0001). For a cut-off of 150 μ g/g, FC had an area under the ROC curve to discriminate between organic and functional disease of 0.718, and 0.872 to discriminate between irritable bowel syndrome and IBD. CONCLUSION: Our study supports the importance of FC as a marker in the evaluation of patients with IBD. The best diagnostic accuracy is obtained at a cut-off value of 150μ g/g
Subject(s)
Humans , Inflammatory Bowel Diseases/physiopathology , Colonic Diseases, Functional/physiopathology , Biomarkers/analysis , Inflammation Mediators/analysis , Feces/cytologyABSTRACT
INTRODUCTION: Diagnostic discrimination between inflammatory bowel disease (IBD) and functional gastrointestinal disorders is complex, as they cause similar signs and symptoms. Faecal calprotectin (FC) is a useful marker in this context, and can be used to select patients who will most benefit from colonoscopy. The aim of this study was to evaluate the utility of FC in discriminating between organic disease and functional disorders. MATERIAL AND METHODS: The study included 264 patients presenting with gastrointestinal complaints consistent with an organic pathology. FC levels were determined and diagnostic accuracy was assessed using the area under the curve obtained from the final diagnosis. RESULTS: Calprotectin levels in organic bowel disease patients were significantly higher (median 254µg/g; 95% confidence interval [CI], interquartile range 105-588.5) than in functional disease patients (95µg/g; 95% CI, 47.25-243.92) (P<.0001). Similarly, in patients with IBD, the values obtained were higher (270.85µg/g; 95% CI, 96.85-674.00) than in those with irritable bowel syndrome (79.70µg/g; 95% CI, 36.50-117.25) (P<.0001). For a cut-off of 150µg/g, FC had an area under the ROC curve to discriminate between organic and functional disease of 0.718, and 0.872 to discriminate between irritable bowel syndrome and IBD. CONCLUSION: Our study supports the importance of FC as a marker in the evaluation of patients with IBD. The best diagnostic accuracy is obtained at a cut-off value of 150µg/g.
Subject(s)
Feces/chemistry , Gastrointestinal Diseases/diagnosis , Inflammatory Bowel Diseases/diagnosis , Leukocyte L1 Antigen Complex/analysis , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Prospective Studies , Young AdultABSTRACT
BACKGROUND: Atrial fibrillation (AF) is associated with a high risk of mortality and morbidity and it commonly coexists with chronic kidney disease. A biomarker of renal function, ß-trace protein (BTP), has been implicated in the progression of cardiovascular disease. The aim of our study was to evaluate the association of BTP with adverse cardiovascular events, bleeding, and mortality in patients with AF. METHODS: In a consecutive cohort of patients with nonvalvular AF receiving anticoagulation treatment, plasma BTP was determined using an automated nephelometer BN ProSpec System (Siemens) and related to estimated glomerular filtration rate (eGFR). We recorded adverse cardiovascular events (stroke, acute coronary syndrome, and acute pulmonary edema), major bleeding, and mortality. RESULTS: We included 1,279 patients (48.6% men), aged 76 years (IQR, 71-81 years), who were followed up for 996 days (IQR, 802-1,254 days). During the follow-up, there were 150 cardiovascular events (annual rate, 3.99%), 57 embolisms (annual rate, 1.54%), and 114 major bleeding events (annual rate, 3.04%), and 161 patients died (annual rate, 4.32%). BTP levels were inversely associated with eGFR (P < .001). High BTP concentrations were significantly associated with embolic events (hazard ratio [HR], 4.64 [1.98-10.86]; P < .001), composite adverse cardiovascular events (HR, 1.93 [1.31-2.85]; P = .001), and mortality (HR, 2.08 [1.49-2.90]; P < .001), even after adjusting for CHAD2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes mellitus, stroke [doubled], vascular disease, age 65 to 74 years, sex category) score and renal function. High BTP was associated with major bleeding events (HR, 1.88 [1.18-3.00]; P = .008), even after adjusting for the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or redisposition, labile international normalized ratio, elderly [> 65 years], drugs/alcohol concomitantly) score. CONCLUSIONS: We suggest that BTP, a proposed renal damage biomarker, may be a novel predictor of adverse cardiovascular events, major bleeding, and mortality in patients with AF. BTP may help refine clinical risk stratification in these patients.
Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/blood , Intramolecular Oxidoreductases/blood , Lipocalins/blood , Myocardial Ischemia/epidemiology , Risk Assessment/methods , Stroke/epidemiology , Aged , Aged, 80 and over , Atrial Fibrillation/drug therapy , Biomarkers/blood , England/epidemiology , Female , Follow-Up Studies , Humans , Male , Morbidity/trends , Myocardial Ischemia/prevention & control , Prognosis , Risk Factors , Stroke/prevention & control , Survival Rate/trendsABSTRACT
BACKGROUND: Beta-trace protein (BTP) and cystatin C (CysC) are novel biomarkers of renal function. We assessed the ability of both to predict major bleeding (MB) in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), compared to other renal function parameters and clinical risk scores. METHODS AND RESULTS: We included 273 patients. Blood samples were obtained within 24h of admission. The endpoint was MB. During a follow-up of 760 days (411-1,098 days), 25 patients (9.2%) had MB. Patients with MB had higher concentrations of BTP (0.98 mg/L; 0.71-1.16 mg/L vs. 0.72 mg/L, 0.60-0.91 mg/L, P=0.002), CysC (1.05 mg/L; 0.91-1.30 mg/L vs. 0.90 mg/L, 0.75-1.08 mg/L, P=0.003), higher CRUSADE score (39 ± 16 points vs. 29 ± 15 points, P=0.002) and lower estimated glomerular filtration rate (eGFR; 66 ± 27 vs. 80 ± 30 ml·min(-1)·1.73 m(-2), P=0.02) than patients without MB; there was no difference in creatinine level between the groups (P=0.14). After multivariable adjustment, both were predictors of MB, while eGFR and creatinine did not achieve statistical significance. Among subjects with eGFR >60 ml·min(-1)·1.73 m(-2), those with elevated concentrations of both biomarkers had a significantly higher risk for MB. Net reclassification indexes from the addition of BTP and CysC to CRUSADE risk score were 38% and 21% respectively, while the relative integrated discrimination indexes were 12.5% and 3.8%. CONCLUSIONS: Among NSTE-ACS patients, BTP and CysC were superior to conventional renal parameters for predicting MB, and improved clinical stratification for hemorrhagic risk.
Subject(s)
Acute Coronary Syndrome/blood , Cystatin C/blood , Hemorrhage/blood , Intramolecular Oxidoreductases/blood , Lipocalins/blood , Acute Coronary Syndrome/complications , Acute Coronary Syndrome/physiopathology , Aged , Aged, 80 and over , Biomarkers/blood , Creatinine/blood , Female , Follow-Up Studies , Hemorrhage/etiology , Hemorrhage/physiopathology , Humans , Kidney Function Tests , Male , Middle Aged , Prospective Studies , Risk FactorsABSTRACT
Beta-trace protein (BTP) is a low-molecular mass protein belonging to the lipocalin protein family, which is more sensitive than serum creatinine for detecting impaired renal function. The aims of the present study were to evaluate whether plasma BTP improves the risk stratification of patients with non-ST-segment elevation acute coronary syndromes and to compare it to cystatin C (CysC), serum creatinine, and estimated glomerular filtration rate. Two hundred twenty-six consecutive patients with non-ST-segment elevation acute coronary syndromes were prospectively included. Blood samples were obtained within 24 hours of hospital admission to measure BTP, CysC, and creatinine. The study end point was all-cause death. Over a median follow-up period of 859 days (interquartile range [IQR] 524 to 1,164), 24 patients (10.6%) died. Decedents had higher concentrations of BTP (1.03 mg/L [IQR 0.89 to 1.43] vs 0.74 mg/L [IQR 0.61 to 0.92], p <0.001), CysC (1.16 mg/L [IQR 0.91 to 1.59] vs 0.90 mg/L [IQR 0.76 to 1.08], p = 0.001), and serum creatinine (1.10 mg/L [IQR 0.87 to 1.46] vs 0.94 mg/L [IQR 0.80 to 1.10], p = 0.004) and a lower mean estimated glomerular filtration rate (60 ± 20 vs 80 ± 24 ml/min/1.73 m(2), p <0.001). After multivariate adjustment, BTP and CysC were predictors of all-cause death, while estimated glomerular filtration rate and serum creatinine concentrations did not achieve statistical significance. In stratified analyses according to kidney function, elevated BTP and CysC were associated with a higher risk for all-cause death. Reclassification analyses showed that BTP and CysC added complementary information to Global Registry for Acute Coronary Events (GRACE) risk score. In conclusion, BTP and CysC levels were associated with all-cause death risk and modestly improved prognostic discrimination beyond the GRACE risk score in patients with non-ST segment elevation acute coronary syndromes.
Subject(s)
Acute Coronary Syndrome/blood , Acute Coronary Syndrome/mortality , Cause of Death , Cystatin C/blood , Intramolecular Oxidoreductases/blood , Lipocalins/blood , Acute Coronary Syndrome/diagnosis , Age Factors , Aged , Aged, 80 and over , Area Under Curve , Biomarkers/blood , Cohort Studies , Confidence Intervals , Creatinine/blood , Disease Progression , Electrocardiography/methods , Female , Glomerular Filtration Rate , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Predictive Value of Tests , Prognosis , Prospective Studies , Risk Assessment , Sensitivity and Specificity , Severity of Illness Index , Sex Factors , Survival AnalysisABSTRACT
SCOPE: The cardioprotective role of resveratrol as part of the human diet is not yet clear. Our aim was to investigate the effect of a grape supplement containing 8 mg resveratrol in oxidized LDL (LDLox), apolipoprotein-B (ApoB), and serum lipids on statin-treated patients in primary cardiovascular disease prevention (PCP). METHODS AND RESULTS: A triple-blind, randomized, placebo-controlled trial was conducted. Seventy-five patients (three parallel arms) consumed one capsule (350 mg) daily for 6 months containing resveratrol-enriched grape extract (GE-RES, Stilvid®), grape extract (GE, similar polyphenolic content but no resveratrol), or placebo (maltodextrin). After 6 months, no changes were observed in the placebo group and only LDL cholesterol (LDLc) decreased by 2.9% (p = 0.013) in the GE group. In contrast, LDLc (-4.5%, p = 0.04), ApoB (-9.8%, p = 0.014), LDLox (-20%, p = 0.001), and LDLox/ApoB (-12.5%, p = 0.000) decreased in the Stilvid® group, whereas the ratio non-HDLc (total atherogenic cholesterol load)/ApoB increased (8.5%, p = 0.046). No changes were observed in hepatic, thyroid, and renal function. No adverse effects were observed in any of the patients. CONCLUSION: This GE-RES reduced atherogenic markers and might exert additional cardioprotection beyond the gold-standard medication in patients from PCP. The presence of resveratrol in the GE was necessary to achieve these effects.
Subject(s)
Apolipoproteins B/blood , Cardiovascular Diseases/prevention & control , Dietary Supplements , Lipoproteins, LDL/blood , Stilbenes/pharmacology , Aged , Female , Follow-Up Studies , Humans , Kidney/drug effects , Kidney/physiology , Lipids/blood , Liver/drug effects , Liver/physiology , Male , Middle Aged , Plant Extracts/pharmacology , Resveratrol , Thyroid Function Tests , Vitis/chemistryABSTRACT
Fundamento y objetivo. Justificar la importancia clínica de la determinación del isoenzima de fosfatasa alcalina (PLAP-like) como marcador en tumores de células germinales (TCG). Pacientes y métodos. Se documentan dos casos clínicos observando el comportamiento de este isoenzima: 1) Niño con germinoma intracraneal en región pineal, 75% de actividad de PLAP-like al inicio (valor normal: 0%), resto de marcadores tumorales negativos, y 2) Niña con teratoma inmaduro de ovario estadio I, elevación de la alfafetoproteína (AFP), 197ng/mL; PLAP-like 5,1% al inicio y 0,7% en recidiva tumoral tras dos años. Se determina PLAP-like valorando la actividad remanente tras termodesnaturalización sérica. Discusión y conclusiones. PLAP-like se comporta como único marcador específico en el primer caso de tumor germinal pineal que justifica su utilidad junto a pruebas de imagen en el diagnóstico de tumores de localización craneal. En el seguimiento, también es crítico el análisis dado que constata la buena respuesta al tratamiento en el primer caso, y en el segundo caso clínico, es el único marcador que complemente la valoración de la recidiva. Concluimos en la relevancia del análisis de este isoenzima como marcador complementario en TCG (AU)
Background and purpose. To determine the clinical relevance of placental-like alkaline phosphatase isoenzyme (PLAP-like) as a marker for germ cell tumours (GCT). Patients and methods. We report the behaviour of this isoenzyme in two patients; 1) A Child with an intracranial germinoma in the pineal region who showed 75% of PLAP-like activity at onset (normal value: 0%), with the rest of the tumour markers being negative, and 2) A girl with a stage I ovarian immature teratoma who had an elevated alpha-fetoprotein (AFP), 197ng/mL, PLAP-like 5.1%, at onset and 0.7% at tumour recurrence two years later. PLAP-like was determined by assessing the remaining activity after heat denaturation of the serum. Discussion and conclusions. PLAP-like constituted the only specific marker in the case of the pineal cell germ tumour, which justifies its use in association with neuroimaging studies in the diagnosis of cranial tumours. At follow-up analysis, PLAP-like was also critical since it confirmed the good response to treatment in the first case, while in the second one, it was the only marker to complement the assessment of tumour recurrence. We believe that this isoenzyme analysis is of relevance as a complementary marker in GCT (AU)
Subject(s)
Humans , Male , Female , Child , Isoenzymes , Alkaline Phosphatase , Biomarkers, Tumor/analysis , Biomarkers, Tumor/isolation & purification , Neoplasms, Germ Cell and Embryonal/diagnosis , Teratoma/complications , Teratoma/diagnosis , Diagnosis, Differential , Alkaline Phosphatase/chemical synthesis , Alkaline Phosphatase/metabolism , Alkaline Phosphatase/pharmacokineticsABSTRACT
BACKGROUND: The atherogenic lipoprotein phenotype is characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol (HDLc), and the prevalence of small, dense-low density lipoprotein cholesterol (LDLc) particles. The aim of this study was to establish the importance of LDL particle size measurement by gender in a group of patients with Metabolic Syndrome (MS) attending at a Cardiovascular Risk Unit in Primary Care and their classification into phenotypes. SUBJECTS AND METHODS: One hundred eighty-five patients (93 men and 92 women) from several areas in the South of Spain, for a period of one year in a health centre were studied. Laboratory parameters included plasma lipids, lipoproteins, low-density lipoprotein size and several atherogenic rates were determinated. RESULTS: We found differences by gender between anthropometric parameters, blood pressure and glucose measures by MS status. Lipid profile was different in our two study groups, and gender differences in these parameters within each group were also remarkable, in HDLc and Apo A-I values. According to LDL particle size, we found males had smaller size than females, and patients with MS had also smaller than those without MS. We observed inverse relationship between LDL particle size and triglycerides in patients with and without MS, and the same relationship between all atherogenic rates in non-MS patients. When we considered our population in two classes of phenotypes, lipid profile was worse in phenotype B. CONCLUSION: In conclusion, we consider worthy the measurement of LDL particle size due to its relationship with lipid profile and cardiovascular risk.
Subject(s)
Lipids/blood , Lipoproteins, LDL/blood , Lipoproteins, LDL/chemistry , Metabolic Syndrome/blood , Adult , Aged , Biomarkers/blood , Body Weights and Measures , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Female , Humans , Hyperglycemia/epidemiology , Hyperglycemia/etiology , Hyperlipidemias/epidemiology , Hyperlipidemias/etiology , Hypertension/epidemiology , Hypertension/etiology , Male , Metabolic Syndrome/physiopathology , Middle Aged , Particle Size , Risk Factors , Sex Characteristics , Spain/epidemiology , Triglycerides/bloodABSTRACT
BACKGROUND: Kidney stones have become increasingly prevalent in the developed countries over the past 100 years. The incidence of urolithiasis in a population depends on the geographical area, racial distribution, socio-economic status and dietary habits. During the past decades, these factors have changed affecting the incidence and also the chemical composition of calculi; nowadays in our region, the most common stones composition is calcium oxalate. The identification of the calculi composition enables superior treatment, lower (decreased) cost and a better quality of life for the patients. METHODS: We analyzed the composition and the evolution of all of the cases concerning calculi received at Biochemical Clinical Analysis Laboratory from 2007 to 2010, using Interferometry with Fourier transformation (FTIR). The relationship between composition, gender and age was studied for an aleatory group in 2010 (n=657, 431 men and 226 women). RESULTS: The stone composition obtained was mixtures 24.7% and only one component 75.3%. Calcium oxalate monohydrate (COM) 41.5%, calcium oxalate dihydrate (COD) 7.6%, anhydrous uric acid (AUA) 12.4%, uric acid dehydrate (UAD) 6.7%, urates 1.4%, carbonate-apatite (CA) 2.9%, and others 2.8%. The male to female ratio was 1.9 and the largest number of stones was found in patients between the ages of 40 and 49, for both men and women. CONCLUSIONS: The most common composition (relative percentage) was COM, mixtures and AUA. Presence of calculi is more common in men than in women with the exception of carbonate apatite stones. Stones follow a Gaussian distribution throughout the lifetime of a patient, with particular incidence in those between 40 to 49 years old.
Subject(s)
Kidney Calculi/chemistry , Kidney Calculi/epidemiology , Adolescent , Adult , Age Distribution , Aged , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Mediterranean Region/epidemiology , Middle Aged , Sex Distribution , Spain/epidemiology , Spectrophotometry, Infrared , Young AdultABSTRACT
No disponible
The biological effects of oxidized LDL (oxLDL) may contribute to initiation and progression of the atherosclerotic process, and the association between cardiovascular disease and oxidation of LDLhas been largely demonstrated. The objectives of this study were to establish the reference values of oxidative stress biomarkers in a young healthy Spanish population to determine the concentration of oxLDL and its relationship with lipid profile and with these biomarkers. oxLDL, F2-isoprostanes, protein carbonyls (PC), and (..) (AU)
Subject(s)
Humans , Receptors, Oxidized LDL/analysis , Lipids/blood , Oxidative Stress , Biomarkers/analysis , Reference Values , Isoprostanes/urine , Triglycerides/blood , Glutathione Reductase/blood , Glutathione Peroxidase/bloodABSTRACT
The biological effects of oxidized LDL (oxLDL) may contribute to initiation and progression of the atherosclerotic process, and the association between cardiovascular disease and oxidation of LDL has been largely demonstrated. The objectives of this study were to establish the reference values of oxidative stress biomarkers in a young healthy Spanish population to determine the concentration of oxLDL and its relationship with lipid profile and with these biomarkers. oxLDL, F(2)-isoprostanes, protein carbonyls (PC), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) were determinate by ELISA in 72 healthy subjects. Antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GR) were carried out on a Hitachi 912 analyzer; lipid profile were assayed using automated systems (Cobas 711, Roche Diagnostics). All statistics were analyzed by using SPSS for Windows 15.0. SPSS Inc, Chicago, IL, USA. (Normal mean reference values): oxLDL (63.23 +/- 16.23 U/L), (Male/Female 68.06 +/- 17.69/58.39 +/- 13.6 U/L), F(2)-isoprostanes (2.26 +/- 0.9 microg/g creatinine), PC (0.34 +/- 0.15 nmol/mg), 8-OHdG (23.27 +/- 10.58 ng/ml), SOD (931.97 +/- 271.09 U/g Hb), GR (46.56 +/- 11.68 U/L), GPx (27.58 +/- 6.89 U/gHb (Male/Female 25.91 +/- 5.03/29.2 +/- 8.07 U/L)). OxLDL (63.23 U/L) was significantly (p < 0.05) positively correlated with BMI (22.53 Kg/m(2)), total cholesterol (175.79 mg/dl), triglycerides (87.58 mg/dl), LDL cholesterol (96.25 mg/dl), and uric acid (4.78 mg/dl), while negatively correlated with HDL-cholesterol (62.25 mg/dl). We have found different correlation between oxLDL and isoprostanes by gender with the rest of parameters. Normal reference values have been found significantly different for oxLDL and GPx by gender. Oxidized LDL is correlated with lipid profile but not with the oxidative stress biomarkers. Urinary isoprostanes are positively correlated with triglycerides and negatively with GR and GPx.
Subject(s)
Biomarkers/metabolism , Lipids/blood , Lipoproteins, LDL/metabolism , Oxidative Stress , 8-Hydroxy-2'-Deoxyguanosine , Adult , Antioxidants/metabolism , Deoxyguanosine/analogs & derivatives , F2-Isoprostanes/metabolism , Female , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Humans , Male , Reference Values , Sex Factors , Spain , Superoxide Dismutase/metabolism , White PeopleABSTRACT
La gestión de una institución se define como la disposición y la organización de los recursos para obtener los resultados esperados. Para aplicar este concepto a un laboratorio clínico es necesario conocer la demanda de las pruebas y su evolución temporal, los resultados informados y el rendimiento. Nuestro objetivo es exponer la gestión del laboratorio de gastroenterología durante los años 2006/2007 y analizar la significación clínica de la calprotectina fecal. Material y métodos. La evaluación de la gestión se realiza considerando el número de determinaciones, los costes económicos y el rendimiento. Respecto a la calprotectina, se estudia la evolución de su demanda, se agrupan los resultados patológicos de 2007 según diagnóstico y se aplica un análisis estadístico ANOVA más un test de Tukey. Resultados y conclusiones. Los datos económicos revelan una buena gestión: aumento en la demanda de las técnicas, disminución del porcentaje de costes y mejora del rendimiento en las pruebas de cribado. Los resultados de calprotectina más elevados corresponden a pacientes con carcinoma colorrectal (significativamente mayores que en grupo misceláneo y sin diagnóstico conocido), seguidos de pacientes aquejados de enfermedad inflamatoria intestinal (AU)
Introduction. The management of an institution is defined as the arrangement and organisation of resources to obtain the expected results. To apply this concept to a clinical laboratory it is necessary to know the test demand and its development over time, the reported results and the performance. Our goal is to explain the management of Gastroenterology Laboratory for the years 2006/2007 and analyse the clinical significance of faecal calprotectin. Material and methods. Management takes into account: the number of determinations, cost and performance. With calprotectin, we examined the evolution of its demand, grouped the results of 2007 according to pathological diagnosis and applied ANOVA statistics and the Tukey test. Results and conclusions. The economic data show a good management: increase in demand for techniques, decrease in percentage of costs and increase in performance of the screening techniques. The results of calprotectin are higher in patients with colorectal carcinoma (significantly higher than in a group with no known diagnosis and a miscellaneous group), followed by patients with inflammatory bowel disease (AU)